{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-005886","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.576994+00:00","generated_at":"2026-06-02T06:22:15.270768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed","bullets":["Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.","Net loss $9.2M ($0.01/share) vs $6.4M loss in Q1 2023; adjusted non-GAAP EBITDA loss $6.2M.","Gross margin 66%; consumable revenue $4.0M (64% of sales), capital revenue $2.2M (+30% YoY).","Cash and securities $90.9M at March 31, 2024, down from $100.5M at Dec 31, 2023.","FY 2024 revenue guidance maintained at $31-35M, up ~39% at high end from $25.2M in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-005886","json":"https://secwatch.observer/filing/0001654954-24-005886.json","markdown":"https://secwatch.observer/filing/0001654954-24-005886.md","text":"https://secwatch.observer/filing/0001654954-24-005886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:22:15.270768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cfe8e5bff18536c28225d69c77087a50184f257","claim":"Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.","evidence_excerpt":"For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$31 to $35 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"32aab08514f08251c05006784eeb4e58d53c0b54","claim":"Zomedica Corp. reported the quarter ended March 31, 2024 results: revenue $6.3 million, net income $9.2 million, EPS $0.01 per share.","evidence_excerpt":"Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics. Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels. Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.3 million"},{"label":"Net income","value":"$9.2 million"},{"label":"EPS","value":"$0.01 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}